WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > NEHTA
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
MedTech
Medtronic plc | October 01, 2021
Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...
Obsidian Therapeutics | September 16, 2020
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...
Industrial Impact, Medical
Globenewswire | April 19, 2023
Merck known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling scienc...
TheHill | April 05, 2020
Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate us...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE